Royalty Pharma Bets Big on Voranigo’s Market Success
Company Announcements

Royalty Pharma Bets Big on Voranigo’s Market Success

Royalty Pharma (RPRX) just unveiled an update.

Servier’s new drug Voranigo has gained FDA approval, promising treatment for patients with a specific type of brain cancer. Under a lucrative deal, Royalty Pharma will pay Agios $905 million for a slice of Voranigo’s future sales, betting on the drug’s success with projected annual sales exceeding $1 billion and generating substantial royalties possibly until 2038. This deal underscores the high stakes and potential rewards in pharmaceutical investments.

For an in-depth examination of RPRX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyGeron announces $375M in synthetic royalty, debt financings with Royalty Pharma
TheFlyRoyalty Pharma to acquire royalty interest in Geron’s RYTELO for $125M
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App